Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ541MR)

This product GTTS-WQ541MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Gastric Cancer, Breast Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ541MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15132MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SYNT-001
GTTS-WQ14804MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SGN-70
GTTS-WQ6635MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DI-17E6
GTTS-WQ8374MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ6658MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DI-17E6
GTTS-WQ7522MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GC-1102
GTTS-WQ8518MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Hu3F8
GTTS-WQ9608MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JNJ-61610588
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW